Sort   by:  
 Page size 
TranscriptomicsBRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma
Prediction of outcome for melanoma patients with surgically-resected macroscopic nodal metastases is very imprecise. We performed a comprehensive clinicopathologic assessment of fresh-frozen macroscopic nodal metastases and the preceding primary melanoma, somatic mutation profiling and gene expressi...
ORGANISM(S): Homo sapiens 
2013-12-10 | E-GEOD-53118 | biostudies-arrayexpress
TranscriptomicsDetermination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information
In patients with metastatic melanoma, the identification and validation of accurate prognostic biomarkers will assist rational treatment planning. Studies based on "-omics" technologies have focussed on a single high-throughput data type such as gene or microRNA transcripts. Occasionally, ...
ORGANISM(S): Homo sapiens 
2014-08-18 | E-GEOD-54467 | biostudies-arrayexpress
UnknownNeoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
Not available
S-EPMC11750705 | biostudies-literature
UnknownExternal validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma.
Not available
S-EPMC6790583 | biostudies-literature
TranscriptomicsExpression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib
Vemurafenib is a BRAF inhibitor with specificity for the most common BRAF mutant encountered in melanomas (BRAFV600E). Vemurafenib suppresses the proliferation of BRAF mutant human melanoma cells by suppressing downstream activation of the MEK/ERK mitogen activated protein kinases. We used microarra...
ORGANISM(S): Homo sapiens 
2014-05-20 | E-GEOD-42872 | biostudies-arrayexpress
UnknownDNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.
Not available
S-EPMC4201072 | biostudies-literature
UnknownPembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Not available
S-EPMC10941196 | biostudies-literature
TranscriptomicsDNA methylation analysis of melanoma progression to brain metastasis
Melanoma is one of the most aggressive and treatment-resistant cancers. It represents the most life-threatening neoplasm of the skin, and its incidence has been increasing for the last three decades. Melanoma evolves from the local transformation of melanocytes to primary tumors, which can metastasi...
ORGANISM(S): Homo sapiens 
2013-09-19 | E-GEOD-44661 | biostudies-arrayexpress
UnknownCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
Not available
S-EPMC4102942 | biostudies-literature
UnknownProteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
Not available
S-EPMC6173697 | biostudies-literature
Sort   by:  
 Page size